Clonit, Innovation and Passion to serve Acute myeloid leukemia (AML) diagnosis and monitoring.
We are pleased to announce the recent introduction of the new Oncohematology line of products in our catalogue.
In the last months our R&D department has been deeply engaged in studying and developing three new specific molecular assays that can help the diagnosis of Leukemia.
The three kits PML-RARA t(15;17)(q22;q21), AML1-ETO t(8;21)(q22;q22) and Inv(16)(p13q22) - CBFB-MYH11, belonging to the new Clonit's Oncohematology line, have been designed following the "Europe Against Cancer (EAC) Guidelines - Leukemia 2003" and they are CE IVD marked according to the IVDD 98/79 CE.
The new molecular assays are based on a one-step Real-Time RT-PCR protocol starting from peripheral blood or bone marrow samples and can be performed on the most common Real-Time PCR Systems.
qRT- PCR shows significant sensitivity in the detection of the translocations or chromosomal abnormalities in patients with Acute myeloid leukemia (AML). Toghether with the cytogenetic analysis it represents an important tool in the screening of acute leukemia patients and should provide useful information for the diagnosis and prognosis even in situations with low patient material and allows patients to be assigned to the appropriate risk group for management and therapy.
Thanks to our passion for health and for a better life, combined with our strong expertise in molecular biology, we are giving our contribution to AML diagnosis and monitoring, helping patients and clinicians fighting AML.
This makes us proud and happy!
Stay tuned on upcoming Clonit innovation news!